Drugs / Vitis vinifera extract
Vitis vinifera extract
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01768520 | Jul 2012 → Oct 2014 | osteoarthritis, knee | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03962296 | Nov 2012 → Jan 2015 | diabetic retinopathy | Hanyang University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vitis vinifera extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01768520 ↗ |
| Known as | Entelon | “Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group” NCT03962296 ↗ |
| Known as | Enteron | “Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks” NCT01768520 ↗ |